Literature DB >> 15306988

Medical treatment of diabetic foot infections.

Benjamin A Lipsky1.   

Abstract

Diabetic foot infections frequently cause morbidity, hospitalization, and amputations. Gram-positive cocci, especially staphylococci and also streptococci, are the predominant pathogens. Chronic or previously treated wounds often yield several microbes on culture, including gram-negative bacilli and anaerobes. Optimal culture specimens are wound tissue taken after debridement. Infection of a wound is defined clinically by the presence of purulent discharge or inflammation; systemic signs and symptoms are often lacking. Only infected wounds require antibiotic therapy, and the agents, route, and duration are predicated on the severity of infection. Mild to moderate infections can usually be treated in the outpatient setting with oral agents; severe infections require hospitalization and parenteral therapy. Empirical therapy must cover gram-positive cocci and should be broad spectrum for severe infections. Definitive therapy depends on culture results and the clinical response. Bone infection is particularly difficult to treat and often requires surgery. Several adjuvant agents may be beneficial in some cases.

Entities:  

Mesh:

Year:  2004        PMID: 15306988     DOI: 10.1086/383271

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  31 in total

1.  Tissue penetration and pharmacokinetics of tigecycline in diabetic patients with chronic wound infections described by using in vivo microdialysis.

Authors:  Catharine C Bulik; Dora E Wiskirchen; Ashley Shepard; Christina A Sutherland; Joseph L Kuti; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2010-10-04       Impact factor: 5.191

Review 2.  The microbiologic profile of diabetic foot infections in Turkey: a 20-year systematic review: diabetic foot infections in Turkey.

Authors:  M Hatipoglu; M Mutluoglu; G Uzun; E Karabacak; V Turhan; B A Lipsky
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-01-23       Impact factor: 3.267

3.  Physicians' knowledge and attitudes in the management of wound infection.

Authors:  Kevin Y Woo
Journal:  Int Wound J       Date:  2014-04-28       Impact factor: 3.315

4.  Skin and soft tissue infections in hospitalised patients with diabetes: culture isolates and risk factors associated with mortality, length of stay and cost.

Authors:  B A Lipsky; Y P Tabak; R S Johannes; L Vo; L Hyde; J A Weigelt
Journal:  Diabetologia       Date:  2010-02-10       Impact factor: 10.122

5.  Application of white blood cell SPECT/CT to predict remission after a 6 or 12 week course of antibiotic treatment for diabetic foot osteomyelitis.

Authors:  Julien Vouillarmet; Myriam Moret; Isabelle Morelec; Paul Michon; Julien Dubreuil
Journal:  Diabetologia       Date:  2017-09-02       Impact factor: 10.122

6.  Efficacy and safety of neutral pH superoxidised solution in severe diabetic foot infections.

Authors:  Fermín R Martínez-De Jesús; Antonio Ramos-De la Medina; José María Remes-Troche; David G Armstrong; Stephanie C Wu; Jose Luis Lázaro Martínez; Juan V Beneit-Montesinos
Journal:  Int Wound J       Date:  2007-10-22       Impact factor: 3.315

7.  Understanding diabetic foot.

Authors:  Sharad P Pendsey
Journal:  Int J Diabetes Dev Ctries       Date:  2010-04

Review 8.  Optimising antimicrobial therapy in diabetic foot infections.

Authors:  Nalini Rao; Benjamin A Lipsky
Journal:  Drugs       Date:  2007       Impact factor: 9.546

9.  Efficacy and safety of sequential intravenous/oral moxifloxacin vs intravenous/oral amoxicillin/clavulanate for complicated skin and skin structure infections.

Authors:  R Vick-Fragoso; G Hernández-Oliva; J Cruz-Alcázar; C F Amábile-Cuevas; P Arvis; P Reimnitz; J R Bogner
Journal:  Infection       Date:  2009-09-18       Impact factor: 3.553

10.  Management of diabetic foot infections in an era of increasing microbial resistance.

Authors:  Sandra Bliss Nelson
Journal:  Curr Infect Dis Rep       Date:  2009-09       Impact factor: 3.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.